Cara Therapeutics, Inc.

Cara Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Cara Therapeutics, Inc. is not very popular among insiders. Cara Therapeutics, Inc. is a good stock to invest in, but there are better stocks to choose.

CARA Therapeutics, Inc. engages in the research, development, and commercialization of pharmaceutica...

News

Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

Ticker Report StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA - Free Report) in a report released on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company's...\n more…

Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

Zolmax StockNews.com assumed coverage on shares of Cara Therapeutics (NASDAQ:CARA - Free Report) in a research note published on Monday. The firm issued a sell rating on the biopharmaceutical company's...\n more…

Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Rating of "Hold" by Brokerages

Ticker Report Shares of Cara Therapeutics, Inc. (NASDAQ:CARA - Get Free Report) have been given an average rating of "Hold" by the six research firms that are covering the company, Marketbeat.com reports. Six...\n more…

Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com

Ticker Report Equities researchers at StockNews.com initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA - Get Free Report) in a report released on Sunday. The firm set a "sell" rating on the...\n more…

CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nCARA stock results show that Cara Therapeutics missed analyst estimates for earnings per share and missed on revenue for the second...\n more…

Cara Therapeutics (NASDAQ:CARA) Announces Earnings Results

Ticker Report Cara Therapeutics (NASDAQ:CARA - Get Free Report) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the...\n more…